Imagine one new drug that can treat four different type 2 inflammation diseases. New Dupixent (dupilumab) has achieved just that by showing improvements across key disease measures in certain patients with asthma, eczema, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis. Dupixent is also being studied further across a broad spectrum of other inflammatory diseases.
Regeneron Pharmaceuticals, Inc. and Sanofi, under a joint global collaboration agreement, announced new analysis reinforcing a robust body of evidence that Dupixent (dupilumab) helps certain diseases with type 2 inflammation. They will present the findings at the American Academy of Allergy, Asthma and Immunology (AAAAI) Virtual Annual Meeting, held from February 26 to March 1, 2021.
Dupixent shows improvement in signs and symptoms in children age 6 years and older with moderate-to-severe eczema that cannot use topical prescription therapies.
Dupixent brings hope to difficult-to-treat patients age 12 years and older with moderate-to-severe asthma. Dupixent helps prevent severe asthma attacks and can lower the amount of oral corticosteroids the patient needs to improve breathing. Dupixent shows long-term efficacy and there is a potential of clinical remission in patients with moderate-to-severe disease with type 2 inflammation.
For adults living with uncontrolled chronic rhinosinusitis with nasal polyposis (CRSwNP), Duplixent treatment is helpful when used with other medicine therapies.
Currently the use of Dupixent is under clinical investigation in health-related quality of life (HRQoL) in patients with eosinophilic esophagitis. In a randomized, placebo-controlled three-part phase 3 study, Dupixent has shown to reduce symptom burden in patients with Eosinophilic Esophagitis (EoE). However, its safety and efficacy have not been fully evaluated by any regulatory authority.
Dupixent was invented using Regeneron’s VelocImmune® technology that utilizes a proprietary genetically-humanized immune system through its genetically-engineered mouse platform to produce optimized fully-human antibodies. Dupixent is a fully-human monoclonal antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins that are key drivers of the type 2 inflammation in certain diseases.
To date, dupilumab has been studied across 50 clinical trials with more than 10,000 patients that have various chronic diseases driven by type 2 inflammation. Globally, Dupixent is also approved in more than 60 countries around the world with more than 200,000 treated patients.
Regeneron and Sanofi are currently studying the efficacy of dupilumab outside the list of approved indications. There is a broad range of diseases driven by type 2 inflammation under investigational study such as pediatric asthma (6 to 11 years of age, Phase 3), chronic obstructive pulmonary disease with evidence of type 2 inflammation (Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), eosinophilic esophagitis (Phase 3), bullous pemphigoid (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), and food and environmental allergies (Phase 2). Dupilumab has not been fully evaluated by any regulatory authority in its safety and efficacy of these conditions.
